RxDoctor Payments Data

Jared Beck, DO

Family Medicine · Warsaw, MONPI 1386083186

Payments from drug & device makers

$888in general payments, 2019–2025

Across 56 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$193
  • GSK$79
  • Novo Nordisk$66
  • Sanofi-aventis U.S. LLC$65
  • Boehringer Ingelheim$63
  • Amgen$57
  • plus $365 from 14 others

What the payments were for

  • Food & beverage$85396%
  • Education$354%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$888 in reported general payments places this provider in the 60th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$43,172
Medicare patients
179
Services billed
873

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$64,967
OzempicSemaglutide34$41,488
JanuviaSitagliptin Phosphate22$24,159
EliquisApixaban27$22,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$18,719
FarxigaDapagliflozin Propanediol18$17,419
XareltoRivaroxaban13$13,988
OxycontinOxycodone Hcl14$11,539
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen169$8,784
LinzessLinaclotide16$8,666
Breo ElliptaFluticasone/Vilanterol20$7,817
SymbicortBudesonide/Formoterol Fumarate17$6,444
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen214$6,365
Gabapentin230$4,459
Oxycodone Hcl181$4,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$63$64,96758 claims
Novo NordiskOzempic$66$41,48834 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$79$30,41747 claims
MerckJanuvia$17$24,15922 claims
AstraZenecaFarxiga, Symbicort$193$23,86335 claims
PfizerEliquis$27$22,92727 claims
Johnson & JohnsonXarelto$11$13,98813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Warsaw

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →